Literature DB >> 8064658

Lobular dissecting hepatitis in juvenile and young adult dogs.

T S van den Ingh1, J Rothuizen.   

Abstract

A specific form of chronic hepatitis is described in 21 dogs. The disease appears to develop in the neonatal and juvenile period. Predominant clinical signs include weight loss, ascites, and jaundice. The liver is small, with a smooth surface or a limited number of hyperplastic nodules. A characteristic feature of the hepatitis is disruption of the hepatic architecture by complete fibrotic dissection of the lobular parenchyma into individual and small groups of hepatocytes with subsequent portal hypertension. This lesion may represent a specific pattern of hepatic reaction in the immature animal, and resembles human neonatal hepatitis.

Entities:  

Mesh:

Year:  1994        PMID: 8064658     DOI: 10.1111/j.1939-1676.1994.tb03219.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  5 in total

1.  Acquired extrahepatic portosystemic shunts in a young dog.

Authors:  Emma J Agg
Journal:  Can Vet J       Date:  2006-07       Impact factor: 1.008

2.  Multiple acquired extrahepatic portosystemic shunts secondary to veno-occlusive disease in a young German shepherd.

Authors:  Dan Fredholm
Journal:  Can Vet J       Date:  2009-07       Impact factor: 1.008

3.  Major HGF-mediated regenerative pathways are similarly affected in human and canine cirrhosis.

Authors:  Bart Spee; Brigitte Arends; Ted Sgam van den Ingh; Tania Roskams; Jan Rothuizen; Louis C Penning
Journal:  Comp Hepatol       Date:  2007-07-31

4.  ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs.

Authors:  Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

Review 5.  Hepatic Fibrosis in Dogs.

Authors:  V M Eulenberg; J A Lidbury
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.